TABLE 3

Insulin sensitivity, β-cell function, and body weight in the TRIPOD and PIPOD studies

VariableBaseline TRIPOD (period 1)Baseline PIPOD (period 2)End PIPOD (period 3)P value (2 vs. 1)*P value (3 vs. 2)*
TRIPOD troglitazone group (n = 27)
    Si (min · μU−1 · ml−1 · 10−4)2.38 ± 1.522.81 ± 2.092.50 ± 2.560.230.57
    AIRg (μU · ml−1 · min−1)453 ± 283479 ± 309392 ± 2070.600.13
    DI913 ± 5181,095 ± 607878 ± 5980.240.12
    Weight (kg)69.1 ± 10.973.0 ± 11.075.0 ± 11.2<0.00010.006
TRIPOD placebo group (n = 32)
    Si (min · μU−1 · ml−1 · 10−4)2.79 ± 2.322.24 ± 1.242.16 ± 1.340.160.72
    AIRg (μU · ml−1 · min−1)593 ± 554382 ± 285484 ± 3570.030.13
    DI1125 ± 687754 ± 542953 ± 6780.0030.14
    Weight (kg)68.3 ± 8.869.4 ± 8.072.3 ± 9.60.150.0004
  • Data are means ± SD from 59 women who had IVGTTs performed at enrollment into to TRIPOD (period 1), at enrollment into PIPOD (period 2, equivalent to end of postdrug washout period for TRIPOD), and end of postdrug washout period in PIPOD (period 3), so that all results were obtained remote from any acute drug effects.

  • *

    * By paired t test.